

# Ilana F Gareen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2613525/publications.pdf>

Version: 2024-02-01

61  
papers

14,849  
citations

172457

29  
h-index

123424

61  
g-index

64  
all docs

64  
docs citations

64  
times ranked

14112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. <i>New England Journal of Medicine</i> , 2011, 365, 395-409.	27.0	8,392
2	The National Lung Screening Trial: Overview and Study Design. <i>Radiology</i> , 2011, 258, 243-253.	7.3	992
3	Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1980-1991.	27.0	884
4	Cost-Effectiveness of CT Screening in the National Lung Screening Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1793-1802.	27.0	471
5	Results of the Two Incidence Screenings in the National Lung Screening Trial. <i>New England Journal of Medicine</i> , 2013, 369, 920-931.	27.0	465
6	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1286.	7.4	391
7	Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry. <i>Journal of Clinical Oncology</i> , 2008, 26, 2155-2161.	1.6	358
8	Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin-resistant <i>Streptococcus pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2002, 35, 556-564.	5.8	339
9	National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. <i>Annals of Internal Medicine</i> , 2009, 150, 104.	3.9	329
10	Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1771-1779.	6.3	283
11	Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 746.	7.4	268
12	Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1928-1935.	5.0	186
13	Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. <i>JAMA Internal Medicine</i> , 2015, 175, 1509.	5.1	148
14	Prognosis in Infiltrating Lobular Carcinoma. <i>American Journal of Surgical Pathology</i> , 1990, 14, 12-23.	3.7	133
15	Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. <i>Cancer</i> , 2014, 120, 3401-3409.	4.1	129
16	National Institutes of Health consensus development conference statement: Management of hepatitis B. <i>Hepatology</i> , 2009, 49, S4-S12.	7.3	91
17	Risk Perceptions Among Participants Undergoing Lung Cancer Screening: Baseline Results from the National Lung Screening Trial. <i>Annals of Behavioral Medicine</i> , 2009, 37, 268-279.	2.9	90
18	The impact of positron emission tomography (PET) on expected management during cancer treatment. <i>Cancer</i> , 2009, 115, 410-418.	4.1	81

#	ARTICLE	IF	CITATIONS
19	The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study*. Critical Care Medicine, 2019, 47, 951-959.	0.9	76
20	The National Oncologic PET Registry (NOPR): Design and Analysis Plan. Journal of Nuclear Medicine, 2007, 48, 1901-1908.	5.0	74
21	A Qualitative Study of Lung Cancer Risk Perceptions and Smoking Beliefs Among National Lung Screening Trial Participants. Nicotine and Tobacco Research, 2014, 16, 166-173.	2.6	62
22	Preferential Use of Sonographically Guided Biopsy to Minimize Patient Discomfort and Procedure Time in a Percutaneous Image-Guided Breast Biopsy Program. Journal of Ultrasound in Medicine, 2002, 21, 1221-1226.	1.7	42
23	Primer on Multiple Regression Models for Diagnostic Imaging Research. Radiology, 2003, 229, 305-310.	7.3	39
24	Impact of <sup>18</sup> F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts. Journal of Nuclear Medicine, 2012, 53, 831-837.	5.0	34
25	The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Cancer Screening Trial: Implications for Public Health. Nicotine and Tobacco Research, 2016, 18, ntv037.	2.6	34
26	Comparative Economic Evaluation of Data from the ACRIN National CT Colonography Trial with Three Cancer Intervention and Surveillance Modeling Network Microsimulations. Radiology, 2011, 261, 487-498.	7.3	33
27	Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up. Cancer, 2013, 119, 1306-1313.	4.1	33
28	Intrauterine Devices and Pelvic Inflammatory Disease: Meta-Analyses of Published Studies, 1974-1990. Epidemiology, 2000, 11, 589-597.	2.7	32
29	Explaining the association of maternal age with cesarean delivery for nulliparous and parous women. Journal of Clinical Epidemiology, 2003, 56, 1100-1110.	5.0	32
30	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	7.1	27
31	Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry. Molecular Imaging and Biology, 2011, 13, 161-165.	2.6	26
32	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. Journal of Oncology Practice, 2016, 12, 1101-1113.	2.5	25
33	Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial?. Clinical Trials, 2016, 13, 434-438.	1.6	24
34	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. JAMA Oncology, 2019, 5, 1036.	7.1	23
35	The National Lung Screening Trial's Endpoint Verification Process: Determining the cause of death. Contemporary Clinical Trials, 2011, 32, 834-840.	1.8	17
36	Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial. Oncologist, 2016, 21, 40-49.	3.7	17

#	ARTICLE	IF	CITATIONS
37	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	7.3	17
38	Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. <i>Journal of Clinical Oncology</i> , 2022, 40, 1407-1413.	1.6	17
39	Hospice Admission and Survival After <sup>18</sup> F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 427-433.	5.0	13
40	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	7.1	13
41	Intended Versus Inferred Treatment After <sup>18</sup> F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 421-426.	5.0	12
42	A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). <i>Cancer</i> , 2022, 128, 1381-1391.	4.1	11
43	[DT0101]: IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1474.	0.8	10
44	Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings. <i>Medical Care</i> , 2018, 56, 403-409.	2.4	10
45	Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial. <i>Patient Preference and Adherence</i> , 2015, 9, 1043.	1.8	9
46	Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial. <i>American Heart Journal</i> , 2016, 179, 19-28.	2.7	7
47	Transportable versus Fixed Platform CT Scanners: Comparison of Costs. <i>Radiology</i> , 2003, 226, 63-68.	7.3	6
48	Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ. <i>JAMA Network Open</i> , 2021, 4, e2129697.	5.9	6
49	Intrauterine devices and pelvic inflammatory disease. <i>Current Women's Health Reports</i> , 2003, 3, 280-7.	0.2	6
50	Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: The model used by the American College of Radiology arm of the National Lung Screening Trial. <i>Contemporary Clinical Trials</i> , 2013, 34, 36-44.	1.8	5
51	Racial Differences in Smoking-related Disease Risk Perceptions Among Adults Completing Lung Cancer Screening: Follow-up Results from the ACRIN/NLST Ancillary Study. <i>Journal of Racial and Ethnic Health Disparities</i> , 2019, 6, 676-685.	3.2	5
52	Noncompliance in cancer screening trials. <i>Clinical Trials</i> , 2007, 4, 341-349.	1.6	3
53	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , .	4.1	3
54	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021, 127, 4546-4556.	4.1	3

#	ARTICLE	IF	CITATIONS
55	Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging. JAMA Network Open, 2022, 5, e2210331.	5.9	3
56	Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. JCO Precision Oncology, 2022, , .	3.0	3
57	Diagnostic quality of mammograms obtained with a new low-radiation-dose dual-screen and dual-emulsion film combination.. American Journal of Roentgenology, 1990, 154, 265-270.	2.2	1
58	Effect of Referring Physician Specialty and Practice Type on Referral for Image-Guided Breast Biopsy. Journal of the American College of Radiology, 2005, 2, 488-493.	1.8	1
59	Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST).. Journal of Clinical Oncology, 2013, 31, 1563-1563.	1.6	1
60	The Potential Impact of Differential Noncompliance In Screening Trials. American Journal of Epidemiology, 2006, 163, S225-S225.	3.4	0
61	Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]. BMC Public Health, 2022, 22, .	2.9	0